Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder

• Status: Withdrawn
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether acceptance and commitment therapy is effective in the treatment of SSRIs-resistant obsessive- compulsive disorder.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

1. age between 18 and 65;

2. no less than 9 years in education;

3. a DSM-IV diagnosis of OCD

4. moderately symptomatic (Yale-Brown Obsessive Compulsive Scale score≥16)

5. received at least two kinds of SSRIs at optimal dose for more than 12 weeks An optimal dose is described as following: clomipramine hydrochloride, at least 225 mg/d;fluoxetine, at least 60 mg/d; paroxetine hydrochloride, at least 60 mg/d; sertraline hydrochloride, at least 200 mg/d; fluvoxamine, at least 250 mg/d; citalopram hydrobromide,at least 60 mg/d; and escitalopram oxalate, at least 40 mg/d.Patients who are unable to tolerate the supposed optimal doses were also eligible if at their maximally tolerated dose.

Exclusion Criteria:

1. with comorbid Axis I psychiatric disorders

2. drug abuse in the last 3 months

3. HAMD>25

4. too severe to receive ACT or evaluation

5. at high risk of suicide

6. pregnant or prepare for pregnancy

7. with somatic disorder

8. received aripiprazole(≥10mg for 8weeks) or ACT(8 times within 2 months) before

9. treated with no more than one kind of SSRI before